SIGA Technologies (SIGA) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue was $6.2 million, down from $7.0 million in Q1 2025, with no international sales recognized in Q1 2026.

• Net loss for Q1 2026 was $3.5 million, or $0.05 per diluted share, compared to $0.4 million, or $0.01 per share, in Q1 2025.

• Special cash dividend of $0.60 per share was declared and paid in April 2026.

• Exclusive license and distribution agreement for oral TPOXX in the MENA region was signed.

• EMA and MHRA confirmed benefit-risk for smallpox but removed mpox from Tecovirimat-SIGA’s label.

Financial highlights

• Product sales and supportive services revenue was $3.5 million in Q1 2026, down from $5.8 million in Q1 2025.

• Research and development revenues were $2.7 million in Q1 2026, up from $1.2 million in Q1 2025.

• Operating loss for Q1 2026 was $5.3 million, compared to $2.3 million in Q1 2025.

• Cash and cash equivalents as of March 31, 2026, were $145.6 million, down from $155.0 million at year-end 2025.

• No outstanding debt as of Q1 2026.

Outlook and guidance

• Over $35 million in oral and IV TPOXX deliveries to U.S. and international customers expected across Q2 and Q3 2026.

• Supplemental NDA submission for smallpox post-exposure prophylaxis targeted within the next twelve months.

• Pediatric program phase I results expected in H2 2026.

• Management expects liquidity and capital resources to be sufficient for at least the next twelve months.

• Long-term outlook remains positive, supported by ongoing government engagement and funding.